Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-31

Study Completion Date

2017-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Alopecia areata (AA) presents with circumscribed patches of non-scarring hair loss. It inflects a significant psychological and social burden. Many treatment options are used for the treatment of AA. Randomized controlled trials comparing intralesional and topical therapy and comparing combinations are few.

The aim of this work is to evaluate the efficacy of combined topical 5% minoxidil and potent topical corticosteroid therapy compared to intralesional triamcinolone injection in alopecia areata

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia

NCT07273799

Androgenic Alopecia

NOT_YET_RECRUITING PHASE3

Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata

NCT06399783

Alopecia Areata

NOT_YET_RECRUITING PHASE4

Minoxidil Response Testing in Males With Androgenetic Alopecia

NCT02198261

Androgenetic Alopecia

COMPLETED

Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia

NCT07080931

Androgenetic Alopecia

RECRUITING PHASE3

The Efficacy and Safety of Different Concentrations of Localized Injections of Steroids in the Treatment of Alopecia Areata

NCT01246284

Alopecia Areata

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alopecia Areata

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intralesional group

intralesional triamcinolone acetonide 5 mg/ml monthly

Group Type ACTIVE_COMPARATOR

Triamcinolone Acetonide

Intervention Type DRUG

Topical therapy group

Minoxidil 5% topical solution applied twice daily and topical clobetasol propionate 0.05% cream applied once daily every night

Group Type ACTIVE_COMPARATOR

Minoxidil 5 % Topical Spray

Intervention Type DRUG

clobetasol propionate

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triamcinolone Acetonide

Intervention Type DRUG

Minoxidil 5 % Topical Spray

Intervention Type DRUG

clobetasol propionate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients presenting with scalp alopecia areata, patchy type, of at least 2 months duration.

Exclusion Criteria

* Alopecia totalis and alopecia universalis.
* Alopecia areata solely affecting the beard.
* Pregnant and lactating.
* Patients known to have autoimmune diseases e.g. autoimmune thyroid disease, vitiligo or SLE.
* Patients receiving systemic treatment relevant to alopecia areata within 3 months before enrollment into the study or topical treatment relevant to alopecia areata within 2 months before.
* Patients with a dermatological condition affecting the scalp other than AA: e.g. psoriasis, eczema.
* Patients with psychiatric illness or psychological state interfering with compliance or influencing the expectation of the patient.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No